1. Deep Transcranial Magnetic Stimulation Combined With Brief Exposure for Posttraumatic Stress Disorder: A Prospective Multisite Randomized Trial
- Author
-
Daniel M. Blumberger, Frederic Deutsch, Kerry J. Ressler, Yiftach Roth, Amit Etkin, Sandeep Vaishnavi, Leah S. Casuto, Mahendra T. Bhati, Lisa Deutsch, Walter Duffy, Mark S. George, David Feifel, Moshe Isserles, Ahava Stein, Kyle A.B. Lapidus, Oscar G. Morales, Abraham Zangen, Aron Tendler, Igor Filipcic, Joseph Zohar, Herbert E. Ward, Alexander Bystritsky, Zafiris J. Daskalakis, Laura Viner, and Corey J. Keller
- Subjects
0301 basic medicine ,medicine.medical_treatment ,Exposure therapy ,Implosive Therapy ,Placebo ,behavioral disciplines and activities ,Article ,law.invention ,Stress Disorders, Post-Traumatic ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Double-Blind Method ,law ,Multicenter trial ,mental disorders ,Clinical endpoint ,Medicine ,Humans ,Prospective Studies ,Deep transcranial magnetic stimulation ,Prefrontal cortex ,Biological Psychiatry ,business.industry ,Extinction (psychology) ,Transcranial Magnetic Stimulation ,030104 developmental biology ,Treatment Outcome ,Anesthesia ,business ,030217 neurology & neurosurgery - Abstract
Background Posttraumatic stress disorder (PTSD) is both prevalent and debilitating. While deep transcranial magnetic stimulation (dTMS) has shown preliminary efficacy, exposure therapy remains the most efficacious, though limited, treatment in PTSD. The medial prefrontal cortex (mPFC) is implicated in extinction learning, suggesting that concurrent mPFC stimulation may enhance exposure therapy. In this randomized controlled multicenter trial, the efficacy and safety of mPFC dTMS combined with a brief exposure procedure were studied in patients with PTSD. Methods Immediately following exposure to their trauma narrative, 125 outpatients were randomly assigned to receive dTMS or sham. Twelve sessions were administered over 4 weeks, with a primary end point of change in 5-week Clinician-Administered PTSD Scale for DSM-5 score. This clinical study did not include biological markers. Results Clinician-Administered PTSD Scale for DSM-5 score improved significantly in both groups at 5 weeks, though the improvement was smaller in the dTMS group (16.32) compared with the sham group (20.52; p = .027). At 9 weeks, improvement continued in Clinician-Administered PTSD Scale for DSM-5 score in both groups but remained smaller in dTMS (19.0) versus sham (24.4; p = .024). Conclusions Both groups showed significant PTSD symptom improvement, possibly from the brief script-driven imagery exposure. While our design was unable to rule out placebo effects, the magnitude and durability of improvement suggest that repeated ultrabrief exposure therapy alone may be an effective treatment for PTSD, warranting additional study. The surprising and unexpected effect in the dTMS group also suggests that repeated mPFC stimulation with the H7 coil may interfere with trauma memory–mediated extinction. Our results provide new insight for dTMS approaches for possible future avenues to treat PTSD.
- Published
- 2020